Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Early HR+/HER2+ Breast Cancer (eMonarcHER)
NCT04752332Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of abemaciclib in breast cancer, sponsored by Eli Lilly and Company. Started May 2021; status: terminated.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04752332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752332.